

524,043

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 February 2004 (19.02.2004)

PCT

(10) International Publication Number
WO 2004/015118 A1

(51) International Patent Classification⁷: C12N 15/86,
C07K 14/07, A61K 39/275, 35/76, C12N 5/10, 15/69

(21) International Application Number:
PCT/EP2003/008359

(22) International Filing Date: 29 July 2003 (29.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2002 01189 7 August 2002 (07.08.2002) DK

(71) Applicant (for all designated States except US): BAVAR-
IAN NORDIC A/S [DK/DK]; 23 Ved Amagerbanen,
DK-2300 Copenhagen S (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HOWLEY,
Paul [GB/AU]; Rose Avenue, Glen Waverly, VIC
3150 (AU). MEISINGER, Christine [DE/DE];
Guido-Schneble-Strasse 66, 80689 München (DE).

(74) Agent: ALT, Michael; Bavarian Nordic GmbH, Fraun-
hoferstrasse 18b, 82152 Martinsried (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: VACCINIA VIRUS HOST RANGE GENES TO INCREASE THE TITER OF AVIPOXVIRUSES



(57) Abstract: The invention concerns an Avipoxvirus comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene. The invention further relates to cells, preferably avian cells, comprising a Vaccinia virus host range gene or a homologue of said host range gene. Moreover the invention concerns the use of a Vaccinia virus host range gene or an homologue thereof to increase the titer of avipoxviruses produced from cells after infection of said cells with the avipoxvirus, wherein the host range gene is expressed in said cells.

WO 2004/015118 A1

Vaccinia virus host range genes to increase the titer of Avipoxviruses

The invention concerns an Avipoxvirus comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene. The invention further relates to cells, preferably avian cells, comprising a Vaccinia virus host range gene or a homologue of said host range gene. Moreover the invention concerns the use of a Vaccinia virus host range gene or an homologue thereof to increase the titer of avipoxviruses produced from cells after infection of said cells with the avipoxvirus; wherein the host range gene is expressed in said cells.

Background of the invention

The poxviridae comprise a large family of complex DNA viruses that replicate in the cytoplasm of vertebrate and invertebrate cells. The family of poxviridae can be divided into the subfamily chordopoxvirinae (vertebrate poxviruses) and entomopoxvirinae (insect poxviruses).

The chordopoxvirinae comprise several poxvirus species that can be used as vectors to express exogenous DNA segments encoding antigens against which an immune response is to be induced. Examples for poxviruses that can be used as live vaccines are Vaccinia virus and avipoxviruses, such as the canarypoxvirus and the fowlpoxvirus.

The use of Vaccinia viruses to engineer viral vectors for recombinant gene expression and for the potential use as recombinant live vaccines has been disclosed in numerous publications (see e.g. Mackett, M., Smith, G.L. and Moss, B. [1982] P.N.A.S. USA 79, 7415-7419; Smith, G.L., Mackett, M. and Moss, B. [1984] Biotechnology and Genetic Engineering Reviews 2, 383-407). To construct recombinant Vaccinia viruses, DNA sequences (genes), which code for foreign antigens are introduced into the genome of the Vaccinia virus under the regulation of suitable poxvirus promoters. If the gene is integrated at a site in

the viral DNA, which is non-essential for the life cycle of the virus, the recombinant Vaccinia virus remains infectious. After infection the recombinant virus expresses the integrated DNA sequence (EP 83286 and EP 110385). The recombinant Vaccinia viruses prepared in this way can be used, on the one
5 hand, as live vaccines for the prophylaxis of infectious diseases, and on the other hand, for the preparation of heterologous proteins in eukaryotic cells.

The use of Vaccinia virus as vector for the development of recombinant live vaccines has been affected by safety concerns and regulations. Most of the
10 recombinant Vaccinia viruses described in the literature are based on the Western Reserve strain of Vaccinia virus. It is known that this strain has a high neurovirulence and is thus poorly suited for use in humans and animals (Morita et al., Vaccine 5, 65-70 [1987]). On the other hand the Modified Vaccinia virus Ankara (MVA) is known to be exceptionally safe. MVA has been
15 generated by long-term serial passages of the Ankara strain of Vaccinia virus (CVA) on chicken embryo fibroblasts (for review see Mayr, A., Hochstein-Mintzel, V. and Stickl, H. [1975] Infection 3, 6-14; Swiss Patent No. 568392). MVA is distinguished by its great attenuation that is to say by diminished virulence or infectiosity while maintaining good immunogenicity. Recombinant
20 MVA useful as vaccines have already been constructed and used in clinical trials. WO 98/13500 discloses a recombinant MVA containing and capable of expressing one or more DNA sequences encoding dengue virus antigens. The foreign DNA sequences were recombined into the viral DNA at the site of a naturally occurring deletion in the MVA genome.

25 Another approach towards the generation of safe and effective poxvirus vaccines utilizes avipoxviruses, e.g. canarypoxvirus and fowlpoxvirus, to express antigens to induce an immune response (US 6,340,462). Avipoxviruses are naturally host-restricted and productively replicate only in
30 avian species and cells (Taylor et al., Vaccine 1995, 13: 539-549). If human cells are infected with an avipoxvirus, heterologous genes are expressed from the viral genome. However, the avipoxvirus does not replicate in the human

cells and there is, thus, no risk that the human being is harmed by productive virus replication. Various recombinant avipoxviruses have been constructed that express e.g. lentiviral gene products (US 5,766,598), cytokines and/or tumor-associated antigens (US 5,833,975) or rabies G glycoprotein (Taylor et al., Vaccine 1995, 13: 539-549). A recombinant canarypox virus expressing the four HIV genes gag, pol, env and nef has already been used in clinical trials (Peters, B.S., Vaccine 2002, 20: 688-705).

Since avipoxviruses productively replicate only in avian cells, these cells have to be used for the amplification of the virus and for the generation of recombinant viruses. Unfortunately, the titers of avipoxviruses obtained with avian cells are relatively low when compared to other poxviruses and it is, thus, more difficult to produce larger amounts of (recombinant) avipoxviruses in an industrial scale.

Object of the invention

It is the object of the present invention to provide means allowing the production of avipoxviruses, in particular recombinant avipoxviruses, at higher titers allowing the production of larger amounts of virus, in particular in an industrial scale.

Detailed description of the invention

According to the present invention vaccinia virus host range genes are expressed in cells productively infected with an avipoxvirus. The expression of these vaccinia virus genes leads to an increase of the avipoxvirus titer produced from the infected cells. As it will be shown in more detail in the example section for a specific embodiment of the invention recombinant avipoxviruses, in particular a canarypoxvirus, expressing a Vaccinia virus host range gene, in particular the Vaccinia virus gene C7L, show a 10 fold increase of the viral titer on avian cells, in particular on Chicken Embryo Fibroblasts

(CEF-cells) compared to the Avipoxvirus lacking the Vaccinia virus host range gene. Although the host range gene is expressed from the recombinant avipoxvirus, the growth on human cell lines is not affected, i.e. the Avipoxvirus expressing the Vaccinia virus host range gene is as attenuated as the
5 Avipoxvirus not expressing the host range gene.

According to a preferred embodiment the invention concerns avipoxviruses comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene.

10

The term "avipoxvirus" refers to any avipoxvirus, such as Fowlpoxvirus, Canarypoxvirus, Uncopoxvirus, Mynahpoxvirus, Pigeonpoxvirus, Psittacinepoxvirus, Quailpoxvirus, Peacockpoxvirus, Penguinpoxvirus, Sparrowpoxvirus, Starlingpoxvirus and Turkeypoxvirus. Preferred
15 avipoxviruses are Canarypoxvirus and Fowlpoxvirus.

20

An example for a canarypox virus is strain Rentschler. A plaque purified Canarypox strain termed ALVAC (US 5,766,598) was deposited under the terms of the Budapest treaty with the American Type Culture Collection (ATCC), accession number VR-2547. Another Canarypox strain is the commercial canarypox vaccine strain designated LF2 CEP 524 24 10 75, available from Institute Merieux, Inc.

25

Examples of a Fowlpox virus are strains FP-1, FP-5 and TROVAC (US 5,766,598). FP-1 is a Duvette strain modified to be used as a vaccine in one-day old chickens. The strain is a commercial fowlpox virus vaccine strain designated O DCEP 25/CEP67/2309 October 1980 and is available from Institute Merieux, Inc. FP-5 is a commercial fowlpox virus vaccine strain of chicken embryo origin available from American Scientific Laboratories
30 (Division of Schering Corp.) Madison, Wisconsin, United States Veterinary License No. 165, serial No. 30321.

The Vaccinia virus host range gene comprised in the viral genome of the avipoxvirus can be any host range gene. The term "Vaccinia virus host range gene" refers to a gene encoding a gene product, which is necessary that a Vaccinia virus is able to replicate on cells of species on which the virus does not replicate in the absence of the functional host range gene. If the respective host range gene is deleted the viral replication may be restricted to cells from only one animal species. By way of example reference is made to the Vaccinia virus genes K1L, C7L and E3L. It has been shown that the expression of either K1L or C7L allows vaccinia virus replication in human MRC-5 cells; the E3L gene was shown to be required for Vaccinia virus replication in monkey Vero and human HeLa cells (Wyatt et al., Virology 1998, 251: 334-342).

The term "Vaccinia virus host range gene for human cells" refers to genes that are required for the replication of the Vaccinia virus in human cells.

Examples for Vaccinia virus host range genes are the genes C18L, C17L, C7L, K1L, E3L, B4R, B23R and B24R according to the nomenclature as used in Johnson et al., Virology 1993, 196: 381-401 and genes (CHO)hr and SPI-1 as specified in Wyatt et al., Virology 1998, 251: 334-342. Preferred host range genes are the host range genes for human cells, e.g. E3L, K1L and C7L. Most preferred is C7L. The nucleotide sequence of the C7L gene of MVA with regulatory sequences is shown in Figure 4 and as SEQ ID: No 1. The corresponding amino acid sequence is shown as SEQ ID: No 2.

The term "homologue of a host range gene" refers to a gene having a homology of at least 50%, preferably at least 70%, more preferably of at least 80%, most preferably of at least 90% in the coding part of the nucleotide sequence, wherein the "homologue of the host range gene" has the biological function of a host range gene. The biological function and definition of a host range gene is defined above. Specific tests how to determine whether a gene has the biological function of a host range gene are known to the person skilled in the art. In particular reference is made to Wyatt et al., Virology 1998, 251:

334-342, Perkus et al., Virology 1990, 179: 276-286 and Gillard et al., J. Virol. 1985, 53: 316-318.

According to the present invention the Vaccinia virus host range gene
5 comprised in the viral genome of the Avipoxvirus is a functional gene. The term
"functional gene" as used in the present application is to be interpreted in that
the host range gene comprises regulatory elements that are functional in cells
productively infected with an Avipoxvirus and that allow the generation of the
functional gene product of the host range gene in said Avipoxvirus infected
10 cells. Thus, the Vaccinia virus host range gene is expressed in the cells.

The term "cells, productively infected with an Avipoxvirus" refers to cells that
allow the propagation of the Avipoxvirus and/or the generation of recombinant
Avipoxviruses. The cells are preferably avian cells, most preferably CEF cells.
15 Other preferred cells are the quail fibroblast cell line QT-35 (Cowen, B.S. and
Braune, M.O., Avian Dis. 1988; 32: 282-297; Schnitzlein, W.M. et al., Virus
Res. 1988; 10: 65-76) or canary embryo cells (Wurtz, S., Bonnet-Piro, E. and
Barban, V., Poster P45 and Wurtz, S. and Barban, V., Poster P93, XIIIth
International Poxvirus and Iridovirus Symposium, Montpellier, France,
20 September 2-6, 2000). Further, it is obvious for a person skilled in the art to
try whether other, commercially available avian cell lines are suitable for the
propagation of Avipoxviruses. Examples for such cell lines obtainable at the
American Type Culture Collection (ATCC) are the quail fibroblast cell lines QT6
(ATCC CRL-1708), QM7 (ATCC CRL-1962), QNR/D (ATCC CRL-2532), the quail
25 cell line QNR/K2 (ATCC CRL-2533), the duck fibroblast cell line Duck embryo
(ATCC CCL-141), the turkey lymphoblast cell line MDTC-PR19 (ATCC CRL-
8135), the chicken fibroblast cell lines SL-29 (ATCC CRL-1590) and
UMNSAH/DF-1 (ATCC CRL-12203) and the chicken lymphoblast cell lines
DT40 (ATCC CRL-2111) and DT95 (ATCC CRL-2112).

30 The regulatory elements comprise inter alia suitable promoter/enhancer and
termination signals that are known to the person skilled in the art as being

active in avipoxvirus infected avian cells. Examples for such promoter/enhancer elements are the Vaccinia virus promoters P_{7.5}, P_{H5}, P₁₁, a synthetic strong promoter P_{syn} (see Genetically engineered viruses, edited by Ring, C.J.A. and Blair, E.D., Bios Scientific Publishers Ltd., 2001, Oxford, UK, ISBN 1 85996 103 7, chapter Vaccinia virus promoters, starting on page 110; Amano, H. et al., Virology 1999, 256: 280-290) as well as the autologous promoters of the Vaccinia virus host range genes.

Fang, Z.-Y. et al., (Virology 2001, 291: 272-284) discloses a recombinant canarypoxvirus that comprises in the viral genome three expression cassettes for HIV gag-pro, gp120/TM and a Nef/Pol poly-epitope string and an expression cassette of the E3L gene. The viral genome of said recombinant further comprises the Vaccinia Virus K3L gene. Due to the presence of the vaccinia virus E3L and K3L genes the apoptosis in infected HeLa cells was significantly reduced and the antigen production in the infected cells was enhanced. Fang et al., does not disclose that the Vaccinia virus host range gene is implicated in any increase of the titer of the recombinant avipoxvirus. Thus, the avipoxvirus according to the present invention is an avipoxvirus comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene, with the proviso that the host range gene is not the E3L gene if the avipoxvirus is a recombinant canarypoxvirus comprising in the viral genome expression cassettes for (I) HIV gag-pro, (II) gp120/TM and a (III) Nef/Pol poly-epitope string as well as for (IV) the Vaccinia virus K3L gene. According to a further alternative embodiment the invention concerns an avipoxvirus comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene, with the proviso that the host range gene is not the E3L gene if the avipoxvirus is a recombinant canarypoxvirus comprising in the viral genome the Vaccinia virus K3L gene.

The Vaccinia virus host range gene is preferably inserted into a non-essential region of the viral genome, into an intergenic region of the viral genome or into

a deletion site of the viral genome. "Non essential regions" are regions that are not required for the replication of the viral genome in avian cells and not needed for the production of infectious viruses. Non-essential regions are known to the person skilled in the art and are disclosed i.a. in US 5,766,598.

5 The insertion of heterologous genes into the Canarypox virus thymidine kinase gene has been disclosed by Amano, H. et al. (Virology 1999, 256: 280-290).

"Intergenic regions" in the viral regions are regions that do not contain coding sequences and preferably no regulatory elements. The location of intergenic regions is known to the person skilled in the art (see e.g. Alfonso C.L. et al., J. Virol 2000, 74: 3815-3831). An example for an insertion into an intergenic region is shown in figure 3 and in the examples section. Thus, it is a preferred embodiment, in particular for a Canarypoxvirus, to insert the host range gene into the intergenic region between the Tk gene and the adjacent X gene.

15

A deletion site is the part of the genome of a modified avipoxvirus that is deleted with respect to the parent avipoxvirus. Deletion sites may be generated by using methods known by a person skilled in the art, starting from a wild type avipoxvirus genome.

20

The Avipoxvirus comprising a Vaccinia virus host range gene may be a wild-type virus comprising as only heterologous gene the Vaccinia virus host range gene, an attenuated virus comprising as only heterologous gene the Vaccinia virus host range gene or a recombinant Avipoxvirus, i.e. a wild-type or attenuated virus comprising further heterologous genes in addition to the Vaccinia virus host range gene.

25

An "attenuated virus" is a virus originating from a pathogenic virus but that upon infection of the host organism leads to a lower mortality and/or morbidity compared to the non-attenuated parent virus. Examples of attenuated poxviruses are known to the person skilled in the art. Examples for attenuated Avipoxvirus strains are i.a. FP-1, ALVAC or TROVAC.

30

The term "recombinant virus" refers to any virus that comprises in addition to the vaccinia virus host range gene an additional heterologous nucleic acid that is not naturally part of the viral genome. A heterologous gene can be, e.g. a therapeutic gene, a gene coding for a peptide comprising at least one epitope to induce an immune response, an antisense expression cassette or a ribozyme gene.

Thus, according to a preferred embodiment the invention concerns Avipoxviruses comprising in the viral genome at least one heterologous nucleic acid sequence in addition to the sequence encoding the Vaccinia virus host range gene, wherein the additional heterologous nucleic acid sequence is preferably selected from a sequence coding for at least one antigen, antigenic epitope, and/or a therapeutic compound.

In a preferred embodiment the present invention concerns the avipoxviruses according to the present invention as a vaccine. A „vaccine“ is a compound, i.e. a vector or a virus that induces a specific immune response.

The heterologous nucleic acids are preferably inserted into the preferred insertion sites of the viral genome as explained above for the Vaccinia virus host range genes. Thus, preferred insertion sites for heterologous nucleic acids are i.a. intergenic regions of the viral genome, deletion sites and non-essential regions.

If the Avipoxvirus is a non-recombinant virus, i.e. an avipoxvirus that does not contain in the viral genome heterologous genes other than the Vaccinia virus host range gene, the Avipoxvirus can be used to vaccinate against avian poxvirus infections. This is of significant importance in the veterinary field, e.g. for the vaccination of poultry. In this case it is preferred to use an attenuated Avipoxvirus. If the Avipoxvirus is a recombinant virus, i.e. an avipoxvirus that contains in the viral genome heterologous genes other than the Vaccinia virus host range gene, the Avipoxvirus can be used to vaccinate against avian

poxvirus infections and/or to induce an immune response against the peptide/protein that is encoded by the additional heterologous nucleic acid. This embodiment is of particular importance if a recombinant Avipoxvirus is used for the vaccination of mammals, in particular humans. In this case the additional heterologous sequence may express antigens against which it is intended to induce an immune response. Examples for such antigens are i.a. tumour antigens, antigens derived from infectious agents such as viruses, bacteria, fungi, synthetic polypeptide strings and so on.

The vaccination is made by administering an Avipoxvirus according to the present invention to an animal, including an human. The mode of administration, the dose and the number of administrations can be optimized by those skilled in the art in a known manner. Most preferred for poxvirus vectors is subcutaneous or intramuscular administration.

For the preparation of a vaccine, the virus according to the invention is converted into a physiologically acceptable form. This can be done based on the experience in the preparation of poxvirus vaccines used for vaccination against smallpox (as described by Stickl, H. *et al.* [1974] Dtsch. med. Wschr. 99, 2386-2392). For example, the purified virus is stored at -80°C with a titer of 5×10^8 TCID₅₀/ml formulated in about 10mM Tris, 140 mM NaCl pH 7.4. For the preparation of vaccine shots, e.g., 10^2 - 10^8 particles of the virus are lyophilized in phosphate-buffered saline (PBS) in the presence of 2% peptone and 1% human albumin in an ampoule, preferably a glass ampoule. Alternatively, the vaccine shots can be produced by stepwise freeze-drying of the virus in a formulation. This formulation can contain additional additives such as mannitol, dextran, sugar, glycine, lactose or polyvinylpyrrolidone or other additives such as antioxidants or inert gas, stabilizers or recombinant proteins (e.g. human serum albumin) suitable for *in vivo* administration. The glass ampoule is then sealed and can be stored between 4°C and room temperature for several months. However, as long as no need exists the ampoule is stored preferably at temperatures below -20°C . For vaccination the

lyophilisate can be dissolved in 0.1 to 0.5 ml of an aqueous solution, preferably physiological saline or Tris buffer, and is administered either systemically or locally; i.e. by parenterally, intramuscularly or any other path of administration known to the skilled practitioner.

5

According to a related embodiment the invention concerns a method for affecting, preferably inducing an immunological response in a living animal body, including a human, comprising administering the avipoxvirus according to the present invention, the pharmaceutical composition and/or or the vaccine according to the present invention to the animal or human to be treated. According to a preferred embodiment the animal may be immuno-compromised. In immuno-compromised animals it is preferred to use severely attenuated virus strains in order to assure that the animal is not overwhelmed by productive virus replication. This may be of particular relevance if the animal is a natural host for the virus, which is the case in poultry. Since Avipoxviruses do not replicate in humans the Avipoxviruses according to the present invention are particularly safe in human beings even if the used virus strain is not an attenuated strain with respect to the natural host.

10

15

20

25

30

According to a further embodiment the invention relates to a pharmaceutical composition comprising the avipox virus according to the present invention and a pharmaceutically acceptable carrier, diluent and/or additive. The pharmaceutical composition is in fact a vaccine if the composition comprises an Avipoxvirus containing in the viral genome a heterologous nucleic acid encoding an antigen against which an immune response is to be induced. However, the heterologous nucleic acid is not restricted to this type of sequences. Instead, the heterologous sequence may also be a suicide gene, such as the herpes simplex virus thymidine kinase gene, a therapeutic gene, such as an antisense RNA gene or ribozyme gene or any other gene having an therapeutic benefit. According to the latter alternatives the avipovirus according to the present invention may be part of a pharmaceutical composition aiming at treating disease and not primarily intending to

vaccinate against a disease. If the heterologous gene is a suicide gene the pharmaceutical composition may be administered locally to a tumour, leading to the infection of the tumour cells with the recombinant avipoxvirus. The suicide gene is then expressed in the tumour cells and by administration of the prodrug that corresponds to the respective gene product of the suicide gene (e.g. gancyclovir in the case of the Herpes simplex virus thymidine kinase gene) a selective killing of tumour cells becomes possible.

The pharmaceutical composition and/or the vaccine may generally include one or more pharmaceutical acceptable and/or approved carriers, additives, antibiotics, preservatives, adjuvants, diluents and/or stabilizers. Such auxiliary substances can be water, saline, glycerol, ethanol, wetting or emulsifying agents, pH buffering substances, or the like. Suitable carriers are typically large, slowly metabolized molecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates, or the like.

According to a preferred embodiment the invention concerns a method for introducing a homologous and/or a heterologous nucleic acid sequence into target cells comprising the infection of the target cells with the avipoxvirus according to the present invention. In the context of this embodiment the terms "heterologous" and "homologous" nucleic acid refer to nucleic acids which are heterologous and homologous, respectively, with respect to the cellular genome. Thus, according to this embodiment a "homologous nucleic acid" is a sequence which is homolog to the cellular genome, such as a cellular gene or a derivative thereof, having a nucleotide sequence homology in the coding region of at least 50%, preferably of at least 70%, more preferably of at least 80%, most preferably of at least 90%. According to this embodiment the term "heterologous nucleic acid" refers to nucleic acids having no homologue in the cellular genome. Examples for such heterologous nucleic acids are viral, bacterial and fungal genes. The target cell may be any cell that can be infected with the virus according to the present invention.

Thus, the target cell may be an avian cell, such as CEF cells, or mammalian cells, including human cells. The cell may be a primary cell or a cell line. The target cell can be a cell that is cultivated in vitro (i.e. a cell that is cultivated in culture flasks) or a cell that is part of a living organism. Methods how to infect
5 cells are known to the person skilled in the art.

The invention further concerns a method for producing a peptide and/or protein comprising the infection of a host cell with the avipoxvirus according to the present invention, cultivation of the infected host cell under suitable
10 conditions, and isolation and/or enrichment of the peptide and/or protein expressed from the viral genome. The peptide/protein may be a Avipoxvirus protein/peptide. If the Avipoxvirus expresses a nucleic acid which is heterologous to the viral genome, the peptide/protein may also be the peptide/protein that is expressed from the heterologous nucleic acid. The host
15 cell type is not critical as long as the cell can be infected with the virus and as long as the protein/peptide to be isolated is produced in said cell from the viral vector. The cell may be a cell in which the virus replicates productively or a cell that does not promote productive replication such as human cells.

20 The invention further concerns a method for producing, in particular amplification of the Avipoxvirus according to the present invention comprising the infection of a host cell with the Avipoxvirus according to the present invention, cultivation of the infected host cell under suitable conditions, and isolation and/or enrichment of the virus produced by said host cell. For
25 amplification of the Avipoxvirus it is necessary to infect cells that allow a reproductive replication of the virus. Such cells are known to the person skilled in the art and include avian cells, i.a. CEF cells. Other suitable cells and cell lines have been disclosed above.

30 The invention further concerns cells infected with the Avipoxvirus according to the present invention. The cells may be cells allowing a productive replication of the Avipoxvirus, such as avian cells, in particular CEF cells or cells that can

be infected by the Avipoxvirus but do not promote viral replication, such as primary human cells or human cell lines.

Methods for obtaining the Avipoxvirus according to the present invention are known to the person skilled in the art (see e.g. US 5,766,598; US 5,833,975; US 6,340,462). According to a preferred embodiment such a method may comprise the following steps: In a first step an avipox virus genome and a DNA comprising a host range gene as defined above are introduced into cells in which the virus is able to reproductively replicate. The avipoxvirus genome may already contain heterologous nucleic acids as defined above. The avipoxvirus genome is conveniently introduced into the cell by infection of the cell with the corresponding avipoxvirus. The DNA is preferably introduced in the cell by transfection techniques known to the person skilled in the art. Such techniques include lipofection or Calcium phosphate precipitation. The DNA that is introduced into the cells is preferably capable to specifically recombine with the genomic DNA of the avipoxvirus. To this end the nucleic acid to be inserted into the viral genome is flanked by viral sequences, which direct a specific recombination of the nucleic acid into the viral genome. Depending on the type of the flanking viral sequences it is possible to insert the nucleic acid into any part of the viral genome. Preferably the insertion is done into non-essential regions of the viral genome, into intergenic regions or into a deletion site.

After the introduction of the viral genome and the DNA comprising a host range gene into cells, virus particles comprising the host range gene in the viral genome are isolated/enriched from these cells in a second step. Methods for the isolation/enrichment of viral particles are known to the person skilled in the art. These techniques include e.g. the use of marker genes in the nucleic acid sequence that is introduced into the viral genome. If the marker gene is a selection marker (e.g. a resistance gene) only those recombinant viruses that contain the marker will replicate in infected cells under selective pressure (e.g. if an antibiotic is present). Alternatively or additionally color markers (e.g. the green fluorescent protein) could be used. If no selection marker is to be used it

is possible to isolate and purify recombinant viruses by limited dilution and/or plaque purification followed by screening of the isolated viruses for the presence of heterologous nucleic acids. Of course these methods may also be combined.

5

Methods for obtaining an avipoxvirus comprising a Vaccinia virus host range gene and at least one additional heterologous nucleic acid are known to the person skilled in the art and correspond basically to the method for obtaining the Avipoxvirus according to the present invention as described above.

10 Basically there are three preferred alternatives: According to a first alternative a DNA comprising the at least one additional heterologous sequence and an avipoxvirus genome already comprising an vaccinia virus host range gene in the viral genome are introduced into cells in which the virus is able to reproductively replicate. As pointed out above the DNA is preferably a DNA
15 that is capable to specifically recombine with the genomic DNA of the avipoxvirus. Then viral particles are isolated/enriched that comprise the at least one additional heterologous sequence in the viral genome from these cells. According to a second alternative a DNA comprising a host range gene as defined above and an avipoxvirus genome already harboring the at least one
20 additional heterologous nucleotide sequence are introduced into cells in which the virus is able to reproductively replicate, wherein the DNA is capable to specifically recombine with the genomic DNA of the avipoxvirus. This is again followed by isolating/enriching virus particles comprising the host range gene in the viral genome from these cells. According to the third alternative an
25 avipoxvirus genome and DNA comprising the vaccinia virus host range gene and the additional heterologous nucleic acid sequence are introduced in the cells. The vaccinia virus host range gene and the additional heterologous nucleic acid sequence may be included in one DNA molecule or the host range gene and the heterologous nucleic acid molecule may be included in different
30 DNA molecules. The further steps in the generation of recombinant viruses are as described above.

As pointed out above the inventors have shown that the expression of vaccinia virus host range genes in cells productively infected with an avipoxvirus leads to an increase of the avipoxvirus titer produced from the infected cells. According to the above embodiments the expression of the vaccinia virus host range genes was achieved by including functional vaccinia virus host range genes into the viral genome of the avipoxvirus, wherein the host range gene is under the regulation of the natural promoter sequence, any other suitable Vaccinia virus promoter, or any other promoter functional in avipoxvirus infected cells.

However, the same results can also be achieved if the functional host range gene is provided by the cell that allows productive replication of the Avipoxvirus. The Vaccinia virus host range gene may be any host range gene as defined above. Preferred host range genes are the Vaccinia virus host range genes for human cells, including the vaccinia virus genes C7L, K1L and E3L. Most preferred is C7L. If not stated otherwise all definitions given above, including the definitions of the viruses, promoters, genes, terms also apply for the following embodiments. Also the order of preferred to most preferred embodiments applies to the following section if not indicated otherwise.

Thus, according to a first alternative of this embodiment the invention concerns a cell comprising a Vaccinia virus host range gene or a homologue of said host range gene, wherein the host range gene is not part of a Vaccinia virus genome. The invention further concerns these cells infected with an Avipoxvirus, i.e. the invention further concerns cells comprising an Avipoxvirus genome. The Avipoxvirus that is to be used for the infection of the cells or the genome of the Avipoxvirus that is comprised in the cell may or may not comprise a Vaccinia virus host range gene or a homologue thereof in the viral genome. Preferably the cell comprising the Avipoxvirus genome comprises a Vaccinia virus host range gene or homologue thereof, wherein the host range gene or homologue thereof is neither part of a Vaccinia virus genome nor part of the Avipoxvirus genome.

The host range gene is preferably a host range gene or a homologue thereof as defined above, i. e. preferably a host range gene for human cells more preferably a host range gene selected from E3L, C7L and K1L.

- 5 The host range gene may be integrated in the cellular genome. Methods to generate cell lines containing a foreign gene in the cellular genome are known to the person skilled in the art. According to this embodiment the most preferred cell lines in which the vaccinia virus host range gene is to be stably integrated are avian cell lines (see above), in particular QT35 cells. According
10 to the present invention the Vaccinia virus host range gene comprised in the cellular genome is a functional gene as defined above.

- Alternatively, the host range gene may be part of a non-integrated DNA. The non-integrated DNA may be a plasmid DNA that has been introduced into the
15 cell by conventional techniques, before or after the cell is infected with the Avipoxvirus. Moreover, the non-integrated DNA may be any DNA that persists in the cell without integrating into the cellular genome. Examples for such a persisting, non-integrating DNA are recombinant viral genomes, such as Herpesviral genomes and vectors derived from Herpesviral genomes.
- 20 According to this embodiment the cell may be any cell allowing the productive replication of Avipoxviruses, including primary cells such as CEF cells.

The Avipoxvirus may be any Avipoxvirus as defined above, including recombinant Avipoxviruses.

25

- In a second alternative of this embodiment the invention concerns a cell comprising a Vaccinia virus host range gene or a homologue of said host range gene and an Avipoxvirus genome, wherein the host range gene or the homologue of said host range gene may or may not be part of the Avipoxvirus
30 genome. If not indicated otherwise the definitions, the preferred embodiments as well as the order of preferred to most preferred embodiments corresponds to that of the first alternative of this embodiment as shown above. In particular

the host range gene may be inserted into the cellular genome or may be part of a non-integrated DNA. However, in addition to the first alternative of this embodiment the second alternative also includes the possibility that the vaccinia virus host range gene or homologue thereof is part of a vaccinia virus genome. Thus, the invention also relates to cells that comprise an Avipoxvirus genome and a Vaccinia virus genome, wherein the Vaccinia virus genome comprises at least one Vaccinia virus host range gene, in particular at least one of the preferred host range genes as defined above. The Vaccinia virus host range genes are expressed and exert a positive effect on the replication of the Avipoxvirus, resulting in an increased amount of Avipoxvirus produced from said cells compared to cells not comprising a Vaccinia virus genome.

Cells comprising a Vaccinia virus genome as well as an Avipoxvirus genome can be easily obtained by infecting a suitable cell with both, a Vaccinia virus and an Avipoxvirus. If the infected cell allows a productive replication of both, Vaccinia virus and Avipoxvirus, the result of the coinfection is a mixture of both viruses. For most applications it is desirable to obtain an Avipoxvirus preparation without Vaccinia virus contamination. To arrive in such a Vaccinia virus free preparation it is possible either to use specific Vaccinia virus strains that infect the cells but that do not productively replicate in said cells or to use specific cells or cell lines that allow the reproductive replication of the avipoxvirus but not of the Vaccinia virus.

The above defined cells according to both alternatives of the present invention can be used in a method for amplifying an avipoxvirus characterized in that the cells comprising a Vaccinia virus host range gene or a homologue of said host range gene are infected with the avipoxvirus. The cells are cultivated and the viral particles produced by said cells are isolated/enriched. Alternatively it is possible either to introduce the Avipoxvirus in the cell before introducing the Vaccinia virus host range gene or to introduce the Avipoxvirus and the Vaccinia virus host range gene at the same time. The avipoxvirus may be any poxvirus as defined above, more particularly a wild-type Avipoxvirus, an attenuated

Avipoxvirus or a recombinant Avipoxvirus lacking a Vaccinia virus host range gene in the viral genome or a wild-type Avipoxvirus, an attenuated Avipoxvirus or a recombinant Avipoxvirus having a Vaccinia virus host range gene in the viral genome

5

Moreover the invention concerns the use of a Vaccinia virus host range gene or an homologue thereof to increase the titer of avipoxviruses produced from avian cells after infection of said cells with said avipoxvirus, wherein the host range gene is expressed in said cells.

10

Furthermore the invention relates to a method for increasing the titer of avipoxviruses produced from avian cells by infecting cells comprising a Vaccinia virus host range gene or a homologue of said host range gene with said avipoxvirus.

15

Short Description of the Figures

Figure 1: Plasmid map of integration vector pBNCaPVX06

The plasmid contain two regions that are homologous to the Canarypox genome (Flank1, corresponding to the sequence of SEQ. ID: No. 3 and Flank 2, corresponding to the sequence of SEQ. ID: NO. 4). These sequences direct the homologous recombination of the sequences located between Flank1 and Flank 2 into the corresponding location of the viral genome. The integration site into the Canarypox virus genome is located between the TK-gene (Thymidine kinase gene) and a gene named Ca.X with unknown function (see Figure 3). NPTII = neomycin resistance gene (expressed from the PS promoter which is a Vaccinia virus strong synthetic promoter); IRES = internal ribosomal entry site; EGFP = enhanced green fluorescence protein. Bsal= restriction enzyme recognition site for Bsal; prT3= T3 promoter sequence derived from plasmid Bluescript pBSK+ (Stratagene, Inc.); prT7= T7 promoter sequence derived from plasmid Bluescript pBSK+ (Stratagene, Inc.). In this description

the designations pBNCaPVX06 and pBNXCaPV06 are used interchangeably and refer to the same plasmid.

Figure 2: Plasmid map of integration vector pBNCaPV08

This plasmid basically corresponds to pBNCaPVX06 explained in the legend to figure 1. pBNCaPV08 additionally comprises the C7L gene derived from MVA (Modified Vaccinia Ankara) expressed from the natural C7L promoter (see Figure 4). The C7L gene from MVA shows the same nucleotide sequence than the C7L gene in Vaccinia virus.

Figure 3: Graphical overview of the intergenic region of the Canarypox genome used for the insertion of Vaccinia virus host range genes. Ca.6, Ca.5, Ca.X, Ca.3: Canarypox virus genes 6, 5, X and 3, respectively; Ca.TK: Canarypox virus Thymidine kinase gene; Flank1 (SEQ. ID: NO. 3) is a DNA fragment comprising parts of the Ca.6 gene, the entire Ca.5 gene and the entire Ca.Tk gene. Flank2 (SEQ. ID: 4) is a DNA fragment comprising the entire Ca.X gene and parts of the Ca.3 gene.

Figure 4: Sequence of C7L region of MVA (Modified Vaccinia Ankara). This sequence corresponds to SEQ.ID:NO 1.

Figure 5: PCR products for the recombinant Canarypoxviruses canBNX01 and canBN01. Figure 5A: PCR product for canBNX01 shown on a 0.8% agarose gel. lane 1: 100bp marker; lane 2: 1 kb marker; lanes 3-5: different canBNX01 isolates; lane 6: CaPV wildtype; lane 7: pBNCaPVX06; lane 8: water control. **Figure 5B:** PCR product for canBN01 shown on a 0.8% agarose gel. lane 1: 100bp marker; lanes 2-4: different canBN01 isolates; lane 5: water control; lane 6: pBNCaPV08; lane 7: CaPV wildtype

Figure 6: Multistep Growth Curve of recombinant CaPV on Various Cell lines. Amplification of canBNX01 (recombinant CaPV comprising the marker

gene cassette but not the Vaccinia virus C7L gene) and canBN01 (recombinant CaPV expressing the C7L gene and the marker gene) in the cell lines BHK-21, Vero, 143B, HaCaT, Hela and MRC-5 and in CEF cells. Virus amplification (fold increase in virus yield above the input level in 6-well-plates) was determined by dividing the virus yield at 96 hours by the input of 5×10^4 (moi 0.05). A ratio of 1,0 means that output = input. The ratios represent the average values of three experiments. Standard errors are indicated by bars.

Figure 7: Nucleotide Sequence of Flank 1 (part A, above) and Flank 2 (part B, below).

Examples

EXAMPLE 1: Construction of recombinant Canarypox canBNX01 (pS NPTII IRES EGFP) and canBN01 (pS NPTII IRES EGFP C7L-MVA)

SUMMARY:

This example describes the generation of recombinant Canarypox virus using NPTII (neomycin resistance gene) and EGFP (green fluorescent protein) selection. The Vaccinia Virus host range gene C7L was cloned into an intergenic region of Canarypox by homologous recombination. After two plaque purifications (PP) there was no wild type virus detectable but only recombinant virus. Sequencing of the integration region showed proper integration and no mutations. RT-PCR showed successful expression of the integrated genes, namely the C7L gene from Modified Vaccinia Ankara and the marker gene cassette. The recombinant virus was shown to be stable up to passage number twenty, even without the selective pressure of Geneticin®.

Introduction:

The aim of this example was to construct a recombinant Canarypox virus expressing the Vaccinia Virus host range gene C7L plus marker cassette

(canBN01) and a recombinant Canarypox expressing the marker cassette alone (canBNX01). Therefore the integration vectors pBNCaPVX06 (see Figure 1) and pBNXCaPV08 (see Figure 2) had been cloned. Both contain two flanks homologous to the Canarypox virus genome, a marker cassette (NPTII =
 5 neomycin resistance, IRES = internal ribosomal entry site, EGFP = enhanced green fluorescence protein) and for pBNCaPV08 additionally C7L derived from MVA (Modified Vaccinia Ankara) expressed by the natural C7L promoter (see Figure 4; SEQ ID: No 1). C7L from MVA shows the same nucleotide sequence as C7L in Vaccinia virus. The marker cassette is expressed by PS promoter
 10 (Vaccinia strong synthetic promoter). The integration site into the Canarypox virus is located in-between the TK-gene (Thymidine kinase) and a gene named Ca.X with unknown function (see Figure 3).

Material:

Recombination vector	pBNCaPVX06 (pBS PS NPTII IRES EGFP) (Fig. 1) pBNCaPV08 (pBS PS NPTII IRES EGFP C7L-MVA) (Fig. 2)
Cells	CEF (Chicken Embryo Fibroblast)
Virus	CaPV crude stock 3.2E+06 TCID ₅₀ /ml
Transfection kit	Effectene (Roche)
DNA-Extraction	Qiagen Blood DNA Kit (Qiagen)
PCR for Wildtype	Taq Polymerase (Roche) Primer:#487: 5'-agcggctttaaatggagatttc-3' Primer: #488: 5'-gttattgttcggaatagaagac-3'
Sequencing	Expand Polymerase (Roche) Big Dye Terminator Kit (PE)
Titration	Anti-CaPV Serum (Guinea Pig #433/1) Anti-Guinea-Pig IgG-POD (Sigma) TMB (Seramun)

Reverse Transcriptase	Rneasy Mini Kit (Qiagen) DNase (Roche) M-MLV RT, RNAsin (Promega) Taq Polymerase (Roche) Primer: #504: 5'-ttacttgtacagctcgtccatgc-3' #505: 5'-atgggatcggccattgaacaag-3' #506: 5'-ggcggcggtcacgaactc-3' #498: 5'-ttaatccatggactcataatc-3' #496: 5'-tatacagcacgaattcgacatcatta-3' #497: 5'-ctatacgggattaacggatgttc-3'
-----------------------	--

Method and Results:

1. Homologous Recombination (HR):

5 Plasmids pBNCaPV09 and pBNCaPVX06 (see Figures 1 and 2) were linearised with Restriction Enzyme BsaI at 50°C over night (cuts in the backbone of the plasmids). The digests were purified with a PCR purification kit (Qiagen) and eluted with 50ul H₂O.

10 CEF cells were seeded into 6-well-plates using RPMI 10% FCS. Next day 60 to 80% confluent cells were infected with CaPV crude stock at a moi of 0.1 and 0.01, respectively. Infection was left for one hour at 37°C, virus suspension was removed, and cells were washed with RPMI and 1.6 ml RPMI 2% FCS were added.

15 Transfection was carried out using Effectene Kit (Roche) following the instruction manual: linearised plasmid (50µl) was mixed with 80µl Buffer EC and 8µl enhancer were added. The solution was mixed and left for 5 min at room temperature. Then 25µl Effectene were added, mixed and left for 10 min at room temperature. Finally 600µl RPMI 2% FCS were added and transferred

onto the cells. The transfection was left for four days at 37°C until fluorescence was detectable. The infection with moi 0.1 seemed to be more effective as clearer fluorescence was detectable. Plates were freeze/thawed three times and finally frozen down at -20°C.

5

2. Passage and Plaque Purification:

As pointed out above the plasmids used to generate recombinant canarypoxvirus contain a Neomycin resistance gene. Thus, it is possible to select for recombinant viruses by adding Geneticin® at a concentration of 10 200µg/ml to the cell culture media.

Preparation of crude virus stock canBNX01:

After transfection/infection (see above) the obtained virus containing suspension was given to fresh CEF cells under selective pressure in 6 well
15 plates. The supernatant of cells in which fluorescent plaques were obtained was used for purification of recombinant virus by limited dilution under selection pressure of Geneticin® and by screening for cells/plaques in which the green fluorescent protein was expressed. The generation of recombinant virus was confirmed by PCR screening which also allowed to detect residual
20 Wildtype contamination. The plaque purification steps were repeated until no Wildtype contamination was detectable by PCR. Nearly confluent T25 flasks of CEF cells were infected with 100µl supernatant of 3 wells in which positive clones for canBNCaPVX01 were detected that were free of wildtype contamination. The media contained Geneticin®. After three days incubation
25 at 37°C positive fluorescence and CPE was detectable. Flasks were freeze/thawed three times and a crude stock was harvested (P7 = passage number seven). An aliquot of 200µl was taken for PCR analysis. The remaining material was frozen at -20°C. The following three passages were conducted in T25 flasks of CEF cells with and without selection pressure of Geneticin®. The
30 working crude stocks (P11) were prepared in T175 flasks of CEF cells with and without Geneticin®. After these passages the recombinant virus was shown to

be stable without Wildtype contamination even in the passages without Geneticin®.

Preparation of crude virus stock canBN01:

- 5 Nearly confluent T25 flasks of CEF cells were infected with 100µl supernatant of 3 wells in which positive clones for canBNCaPV01 were detected. The further purification was done in the same manner as described above.

3. PCR Analysis of recombinant Virus and Wildtype

10

DNA	5.0µl
H2O	2.95µl
x10 buffer	1.0µl
dNTPs	0.2µl
15 Primer #487	0.4µl
Primer #488	0.4µl
Taq Polymerase	0.05µl

PCR coditions:

- 20 94°C, 5min; 94°C, 30sec; 53°C, 30sec; 68°, 3min; 35 cycles; 68°C, 7min; 4°C hold

Controls: pBNCaPVX06 and pBNCaPV08 (plasmids used for integration)
DNA from Canarypox (CaPV) (control for Wildtype)
25 Water control

Size of expected PCR-Products:

pBNCaPVX06 and recombinant virus (canBNX01): 2734bp
pBNCaPV08 and recombinant virus (canBNX01): 3461bp
30 CaPV: 436bp

The PCR analysis (Figure 5A and 5B) has clearly demonstrated that recombinant virus was produced and that the purified viruses were free of input wildtype virus.

5 **4. Sequencing of inserted genes**

Sequencing was conducted with the ABI Prism sequencing machine according to the manufacturers instructions. A PCR product created with primers #487, #488 and Expand Polymerase was used for sequencing. This PCR product includes partly the integration flanks (F1, F1) and entire NPTII IRES EGFP and C7L regions. The expected sequence could be confirmed.

5. Titration of crude stocks canBNX01 and canBN01P11

Virus titers were determined in double titrations and the average titer was calculated as follows:

canBNX01 plus Geneticin®:	4.9E+06 TCID ₅₀ /ml
canBNX01 without Geneticin®:	3.7E+06 TCID ₅₀ /ml
canBN01 plus Geneticin®:	1.3E+07 TCID ₅₀ /ml
canBN01 without Geneticin®:	2.2E+06 TCID ₅₀ /ml

6. RT-PCR as expression test

6.1 RNA-Preparation

CEF cells were seeded into 6-Well-Plates (5 x 10⁵ cells per well DMEM 10% FCS) and infected the following day with 100µl of canBNX01 and canBN01, respectively. Infection was left for two days until fluorescence was detectable. RNA-Extraction was conducted with Rneasy Mini Kit (Qiagen) according to manufacturers instructions. RNA concentration was measured by OD.

6.2 DNase digest for RT-PCR

RNA	25µl
DNase (RNase-free)	3µl
10x buffer A (Roche)	5µl

H₂O (RNase-free) ad 50µl

90min at 37°C

- 5 Digest was cleaned up using Rneasy Mini Protocol for RNA Clean up and RNA concentration was measured by OD.

6.3 Reverse Transcriptase

- 10 RNA and Primer #504 (for canBNX08) or #498 (for canBN01) were mixed in a ratio of 2µg RNA to 1µg primer. Water (RNase-free) was added up to a total volume of 10µl. The mixture was left for 5 min at 70°C and then it was incubated on ice.

The following was added:

15	5x buffer	5µl
	dNTP	5µl
	Rnasin	0.5µl
	M-MLV RT	2µl
	H ₂ O (RNase-free)	2.5µl

60min 42°C

20

RT was cleaned up using PCR purification Kit (Qiagen).

6.4 PCR (Taq Roche)

25	DNA	5µl
	x10 buffer	5µl
	dNTP	1µl
	Primer 1	2µl
	Primer 2	2µl
	Taq (Roche)	1µl

30

PCR conditions:

94°C, 5min; 94°C, 30sec; 58°C, 30sec; 68°C, 2min 30sec; 30 cycles; 68°C, 7min; 4°C hold

- 5 Samples: RNA before RT-PCR (to detect contaminant DNA)
 RNA after RT-PCR and clean up
- Control: pBNCaPVX06 and pBNCaPV08 (positive controls)
- Primer: #505, #506 for canBNX01
 #496, #497 for canBN01
- 10 Size of expected PCR-Products:
 pBNCaPVX06 and recombinant virus (canBNX01): 2188bp
 pBNCaPV08 and recombinant virus (canBN01): 428bp

- 15 The expression of the inserted genes could be confirmed as positive by RT-PCR.

Conclusion:

- With the described method it was possible to construct a recombinant Canarypox virus comprising the Vaccinia virus C7L gene. The C7L gene is
20 derived from MVA (Modified Vaccinia Ankara) and shows the same nucleotide sequence as the C7L gene in Vaccinia Virus Copenhagen.
- The selection method was shown to be very effective since there was no Wildtype virus detectable after two plaque purifications.
- Sequencing of the inserted genes and parts of the surrounding flanks showed
25 no mutations that affect the function. RT-PCR showed the expression of the Vaccinia host range gene C7L under regulation of the natural promoter.

- EXAMPLE 2: Multistep growth curve analysis of recombinant Canarypox**
30 **canBNX01 (pS NPTII IRES EGFP) and canBN01 (pS NPTII IRES EGFP C7L-MVA)**

SUMMARY:

The aim of this example was to investigate replication of a recombinant Canarypox virus expressing the human (tissue culture) host range gene C7L under regulation of the natural promoter in a multistep growth curve on several cell lines. Multistep growth curve means that infection is performed on a low moi (multiplicity of infection), which enables to investigate viral spread and replication. The results indicate that the recombinant Canarypox has improved growth properties on CEF cells resulting in titers, which are one log higher than those of the control virus expressing the marker cassette only. The replication properties on several mammalian cell lines (human, monkey and rabbit cell lines) remains non-effected, which means that the recombinant virus seems to be as attenuated as the control virus.

Introduction:

This example evaluates the growth potential of recombinant Canarypox virus expressing C7L (canBN01; for cloning details see example 1) and the control virus not expressing the C7L gene (canBN01; see example 1) in different cell lines or primary cells. The cell lines/cells used are cell that are permissive for the canarypoxvirus, such as CEF cells and cell lines that are non-permissive for the canarypoxvirus, such as BHK-21, Vero, 143B, HaCaT, Hela, MRC-5 and RK-13 cells. Canarypox is known to be strictly restricted to grow only in avian cells as represented by the primary CEF cells (Esposito et al, 1991; Plotkin et al, 1995, Taylor et al, 1995). Unfortunately, the viral titers are relatively low when compared to other poxviruses, for example MVA. Therefore, the growth properties of a recombinant Canarypox virus expressing the human Vaccinia Virus host range gene C7L (Perkus et al, 1990; Oguiura et al, 1993) were evaluated in CEF cells and it was checked whether the recombinant virus is still not capable replicate on mammalian cell lines.

Material:

Cell lines: CEF: Chicken Embryo Fibroblast, primary cells
BHK-21: Baby Hamster Kidney cells, fibroblast cell line

Vero: African green monkey kidney cells, fibroblast cell line

143B: human Osteosarcoma cell line, TK⁺

HaCaT: human keratinocyte cell line

Hela: human cervix carcinoma cell line, epithelial

5 MRC-5: human lung cell line, fibroblast

RK-13: rabbit kidney cell line, epithelial

All cells are cultured in DMEM 10%FCS

10 Virus: can BNX01, recombinant Canarypox virus expressing marker
cassette only (NPTII, IRES, EGFP; regulated by pS strong
synthetic promoter)
canBN01, recombinant Canarypox virus expressing marker
cassette (NPTII, IRES, EGFP; regulated by pS strong synthetic
promoter) and C7L from MVA regulated by the natural promoter

15

Cell Culture Medium: DMEM plus 2% FCS
DMEM, Gibco
FCS, PAA

20 Other Reagents: RPMI, Gibco; Antibiotic-Antimycotic, Gibco; PBS, Gibco
Trypsin EDTA (1x), Gibco; Fixing solution: Aceton/Methanol
1:1; Incubation solution: PBS plus 3% FCS; Anti-CaPV
Serum (Guinea Pig #433/1); Anti-Guinea-Pig IgG-POD
(Sigma); Staining solution: PBS plus TMB (Seramun) 1:1

25

Methods:

Infection of various cell lines in six-well-plates

Each cell line was grown to nearly confluency in three six-well tissue culture
dishes for each of both viruses. The cell monolayers were infected at a moi
30 (multiplicity of infection) of approximately 0.05 using a total of 5×10^4
TCID₅₀/ml in 500µl of DMEM for each well. Infection was left for one hour at

37°C, then cells were washed two times with DMEM to remove unadsorbed virus and incubated with 1000µl DMEM 2% FCS for four days at 37°C 5% CO₂. After the infection the cells were scraped into the medium and cells plus medium were freeze-thawed three times to release the viruses from the cells.

5 These viral extracts were titered on CEF cells.

Titration of CaPV (Immunostaining with a Canarypox virus specific antiserum):

Titration was performed on CEF cells. Briefly, test cells (CEF) were seeded on 96-well-plates in RPMI 1% Antibiotic/Antimycotic 7% FCS at a concentration of 1 x 10⁴ cells/well and incubated over night at 37°C 5% CO₂. The test samples had already been frozen/thawed 3 times; dilutions of 10⁻¹ to 10⁻¹² were prepared using RPMI medium. Virus dilutions were distributed onto test cells and incubated for five days at 37°C 5% CO₂ to allow CPE development. Test cells were fixed for 10 min, washed with PBS and incubated with polyclonal Canarypox specific antiserum at a 1:1000 dilution in incubation buffer for one hour at RT. After washing twice with PBS the HPR-coupled anti-Guinea-Pig antibody was added at a 1:1000 dilution in incubation buffer for one hour at RT. Cells were again washed twice with PBS and incubated with staining solution until blue spots were visible (15 min). Staining solution was removed and cells were washed with PBS. Every well showing a brown spot was marked as positive for CPE and titre was calculated using the formula of Kaerber (TCID₅₀ based assay) (Kaerber, G. 1931. Arch. Exp. Pathol. Pharmacol. 162, 480).

25 **Results:**

Recombinant Canarypox virus expressing the Vaccinia Virus host range gene C7L was used to infect triplicate sets of CEF, BHL-21, Vero, 143B, HaCaT, Hela, MRC-5 and RK-13 cells at a low multiplicity of infection (moi 0.05). After infection the virus inoculum was removed and cells were washed two times to remove any unabsorbed free virus particle. Then, infections were left for 4 days; virus extracts were prepared and titrated on CEF cells. Figure 6 plots the ratios of Output/Input for the 6-well plates (Output means total virus

production after four days, and Input means the amount of virus used for the initial infections). These ratios give a clear indication of the extent of viral amplification in the various cell types.

- 5 As clearly visible, the recombinant Canarypox expressing C7L (canBN01) shows on CEF cells approximately 10 fold higher titers than the control virus (canBNX01). This means an enhancement of about one log for the titer.

10 When compared to the level of amplification that occurred in all of the mammalian cell lines tested (100 to 1000 fold decreases above input), canBN01 does seem to be severely growth restricted in the cell lines tested. The expression on a Vaccinia Virus human host range gene does not seem to affect replication of Canarypox on mammalian cell lines. Figure 6 clearly demonstrates that amplification by cell-to-cell spread of canBN01 in the cell
15 lines tested cannot be detected.

Conclusion:

The genetic engineering of Canarypox resulting in expression of the Vaccinia Virus human host range gene C7L under regulation of its natural promoter
20 (derived from MVA; Modified Vaccinia Ankara) is useful to increase viral titers on CEF cells. Canarypox is known to grow to relatively low titers and to grow slower than the other poxviruses (for example MVA). Therefore, Vaccinia virus host range genes are a good tool to increase the production of Canarypox without affecting the attenuated replication properties on a range of
25 mammalian cells.

References for Example 2:

- Esposito, J. J. et al.: Arch. Virol. Suppl. (1991) 2, 79-102.
Oguirua, N. et al.: Journal of General Virology (1993) 74, 1409-1413.
30 Perkus, M. et al.: Virology (1990) 179, 276-286.
Plotkin, S. A. et al.: Dev Biol Stand. Basel, Karger (1995) Vol. 84, 165-170.
Taylor, J. et al.: Vaccine (1995) Vol. 13, No. 6, 439-549.

Claims

1. Avipoxvirus comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene, with the proviso that the host range gene is not the E3L gene if the avipoxvirus is a recombinant canarypoxvirus comprising in the viral genome the Vaccinia virus K3L gene as well as expression cassettes for HIV gag-pro, gp120/TM and a Nef/Pol poly-epitope string, respectively.
2. Avipoxvirus according to claim 1, wherein the Vaccinia virus host range gene is a host range gene for human cells.
3. Avipoxvirus according to anyone of claims 1 to 2, wherein the host range gene is selected from the Vaccinia virus genes E3L, C7L and K1L.
4. Avipoxvirus according to anyone of claims 1 to 3, selected from the group consisting of Fowlpoxvirus and Canarypoxvirus.
5. Avipoxvirus according to anyone of the claims 1 to 4 comprising in the viral genome at least one additional heterologous nucleic acid sequence.
6. Avipoxvirus according to claim 5, wherein the additional heterologous nucleic acid sequence is selected from a sequence coding for at least one antigen, antigenic epitope, and/or a therapeutic compound.
7. Pharmaceutical composition comprising the avipox virus according to anyone of claims 1 to 6 and a pharmaceutically acceptable carrier, diluent and/or additive.
8. Vaccine comprising the avipoxvirus according to anyone of claims 1 to 6.

9. The virus according to anyone of claims 1 to 6, the composition according to claim 7 or the vaccine according to claim 8 as drug for affecting, preferably inducing, an immunological response in a living animal, including a human.

5 10. Use of the virus according to anyone of the claims 1 to 6 for the preparation of a medicament or a vaccine.

11. Method for introducing a homologous and/or a heterologous nucleic acid sequence into target cells comprising the infection of the target cells with the
10 virus according to claim 5 or 6.

12. Method for producing a peptide, protein and/or virus comprising the steps of infection of a host cell with the virus according to anyone of claims 1 to 6, cultivation of the infected host cell under suitable conditions, and isolation
15 and/or enrichment of the peptide and/or protein expressed from the viral genome and/or of the virus produced by said host cell.

13. Method for affecting, preferably inducing an immunological response in a living animal body including a human comprising administering the virus
20 according to anyone of the claims 1 to 6, the composition according to claim 7 or the vaccine according to claim 8 to the animal or human to be treated.

14. The method according to claim 13, wherein the animal is immuno-compromised.

25

15. A cell containing the virus according to any of claims 1 to 6.

16. Method for obtaining the avipox virus according to anyone of claims 1 to 6 comprising the following steps:

30 - introducing an avipox virus genome that optionally comprises in the viral genome heterologous nucleic acids as defined in anyone of claims 5 to 6 and a DNA comprising a host range gene as defined in anyone of claims

1 to 3 into cells in which the virus is able to reproductively replicate, wherein the DNA is capable to specifically recombine with the genomic DNA of the avipoxvirus

- isolating/enriching virus particles comprising the host range gene in the viral genome from these cells.

17. Method for obtaining the avipoxvirus according to anyone of claims 5 to 6, comprising the following steps:

- introducing the genome of an avipoxvirus according to anyone of claims 1 to 4 and a DNA comprising the at least one additional heterologous sequence into cells in which the virus is able to reproductively replicate, wherein the DNA is capable to specifically recombine with the genomic DNA of the avipoxvirus
- isolating/enriching virus particles comprising the at least one additional heterologous sequence in the viral genome from these cells.

18. Cell, in particular an avian cell, infected with an avipoxvirus and a Vaccinia virus, wherein the Vaccinia virus comprises at least one Vaccinia host range gene or a homologue thereof in the viral genome.

19. Cell, in particular an avian cell, comprising a Vaccinia virus host range gene or a homologue of said host range gene, wherein the host range gene or the homologue of said host range gene is not part of a Vaccinia virus genome.

20. Cell according to anyone of claims 18 to 19, wherein the host range gene is a host range gene as defined in anyone of claims 2 to 3.

21. Cell according to anyone of claims 19 to 20, wherein the host range gene is integrated in the cellular genome.

22. Cell according to anyone of claims 19 to 20, wherein the host range gene is part of a non-integrated DNA.

23. Cell according to anyone of claims 19 to 22, infected with an avipoxvirus.

5 24. Cell according to claim 23, wherein the avipoxvirus is a recombinant avipoxvirus.

25. Cell according to anyone of claims 23 to 24, wherein the host range gene or the homologue of said host range gene is not part of the genome of the Avipoxvirus.

10

26. Cell according to anyone of claims 15 and 18 to 25, wherein the cells allow the reproductive replication of the avipoxvirus


15 27. Use of a Vaccinia virus host range gene or an homologue thereof, in particular a host range gene as defined in anyone of claims 2 to 3 to increase the titer of avipoxviruses produced from avian cells after infection of said cells with said avipoxvirus, wherein the host range gene is expressed in said cells.

20 28. Method for increasing the titer of avipoxviruses by infecting cells as defined in anyone of claims 19 to 22 with said avipoxvirus or by cultivating cells as defined in anyone of claims 15, 18 and 23 to 25, wherein the cells are cells allowing the productive replication of the avipoxvirus.

25


1/7

Fig. 1




2/7

Fig. 2



3/7

Fig. 3



4/7

Figure 4:

attaataaactttaagacatgtgtgttataactaagatgggttggttattccatagtagcttgtggaatttata
taattatttgaaattctgtacacacaaatgatgtctaccaacogaataaggtatcatcgacaccttaaataat

estimated natural promoter sequence for C7L in MVA

aacttatgatagtaaaactagtagccaatgatgtaaagatgaaaaagtaaattactattaacgccgtoggtatt
tgaatactatcattttgatcatgggttatacatttctactttttcatttaataatgataattgcggcagccataa

cgttcatccattcagtatgggtatacagcagcaattcgacatcattattaatggagatatcgcggttgagaaat
gcaagtaggtaagtcatacccatatgtcgtgcttaagctgtagtaataattacctctatagcgcaactcttta

► M G I Q H E F D I I I N G D I A L R N

ttacagttacataaagggaataactacggatgcaactaaaaattatttcgaatgattacaagaaattaaagt
aatgtcaatgtattttccctatttgatgcctacgtttgatttttaataaagcttactaatgttctttaatttca

► L Q L H K G D N Y G C K L K I I S N D Y K K L K

ttagattcattatacgcagcagattgggtcggaatcgacgaggtcaaaggattaacggtatttgcaacaacta
aatctaagtaataatgcgggtctaaaccagccttttagctgctccagtttcttaattggcataaacggtttgttgat

► F R F I I R P D W S E I D E V K G L T V F A N N Y

C7L gene from MVA

tgcggtgaaagttaataaggtagatgacacgttctattacgtaataatagaggctgtaatacatctgtataac
acgccactttcaattattccatctactgtgcaagataatgcattatatactccgacattatgtagacatattg

► A V K V N K V D D T F Y Y V I Y E A V I H L Y N

aaaaaacagagatatgtatttattctgatgatgagaacgaactctttaaacactattacccatacatcagtc
ttttttgtctctataactaaataagactactactcttgcttgagaaatttgatgataatgggtatgtagtcag

► K K T E I L I Y S D D E N E L F K H Y Y P Y I S

taaataatgattagtaaaagtataaagttaaagaagaaaactactcatcccgatataagaacatccggttaat
atttataactaatcatttttcatatttcaatttcttcttttgatgagtaggggcataatcttctgtaggcaatta

► L N M I S K K Y K V K E E N Y S S P Y I E H P L I

cccgtagagattatgagtcctatggattaa
gggcataatctctaatactcaggtacctaatt

► P Y R D Y E S M D •

5/7

Figure 5A:




Figure 5B:





Figure 6:



7/7

Figure 7A:

ATACTATTCTTCACGGTACATTTAAAAAAGGAATATAGTCAGAAACAGGAAATATACT
TTCACTATAACATGGTCTAATTTTCGAATGTCCGACGTTAGGAGACGTTAAGTCTTCTTC
ACCTAATACCTGTAATAGAGTAGTTTTAGACGGTAGTAGATACGTTACAAAACCTTTA
ATGATACAATATAAATGGAACCTAAGTAGAGAAACGCTGATATTTGTAGGCATTACTGTA
CTAGTAGTAGTAATGATCATATCTGGTTTTCTCACTAATATTGCGATTGATACCTGGTGT
ATATTCATCAGTTATTAGATCGTCGTTTCGTAGGAGGGAAAATATTAAGATTTATGGAGG
TATTCTCTACTGTTATGTTTATACCATCATTAGTAATACTTTTATACAGCATATATAAGG
AAATCTAAAGTGAAAAATACTAAATATTATAGTATTTGTAATAAATGGCTACTGGAGA
GATTCGTCTTATTATAGGGCCTATGTTTTTCAGGTAAACAACAGAATTAGTTAGATTAA
TAAGAAGATTTATGATATCGGGACGTAAATGTATAATAATAAACATTGTAGTGATTCC
CGTTATACCGAAGGAGATTTAGAAGCTATATATACTCATGATAAAATTTTCGATGGAAGC
ACTATCGTGTAGCAAATTATTACCTTTAATACCTAAAAATTGATAACTTTGAAGTAATAG
GTATAGACGAAGGACAGTTTTTTTGAAGATATAGTAGAATTTAGTGAGATTATGGCTAAT
AAGGGTAAAACGTGAATCATAGCGGCTTTAAATGGAGATTTCAAACGACAATTATTTGG
AAACATATTTAAACTATTATCTTTATCAGAATCAGTTACTAGTTTAACTGCTATTTGTG
CAGTTTGTAAAAACGAAGCATCTTTTTCTAAGCGCATGACTGATGATAAAGATGTAAAA
GTTATAGGAGGTAAAGAAATGTATACTGCTGTTTGTAGAAAATGCTTTTTTATGAGTC

Figure 7B:

TAATATACGTACTAAATACTTGTACGTACAACCTATGTTAGAATAATTTGCTTAGTATAG
TATATAAACAAGTATGTAAAAAATAAAATTGATATAAAAGTAGTCTTCTATTCCGAACA
ATAACTATACAAAATGGATTTAGATATTAAATCTTGCAGAAGTATTTACAAAATATGGG
ATAAATATCATTTTATGACAGGGTATAAATATAAAAATGATAAACAGAGATTTAAAATT
ACAATTTACTGTAAATGTGATTGTTCTATCAAAGAATATCCTTTATAGATTTGTTACTGA
GAACTGCTTTTAAATGTATATTATTAATAAGTTTAGAGGAAAGTATCTAATCAAAATTA
GGATAGAACCCATAGTTAAAAATTAAATCATATATCAATACATGTCAGTTTTTTATCGA
AAAATGGATTTATAAATAAAATGAAAAATAACTTGAATGAAGGAAAAATAACCATGAG
TAAAAAACCAGTAAAGACGGTCCAGCGTAGACGTGGAAACGATGAGGATAATAAGTTTA
CTTGTATCCAAGCGCTAGAACATGCAAAAAGCTTATGTACTAAAAATAATAAAATAGTT
AAATCTGTAAACTATCACAATCTCTCTTTAAGTCATCTAACAATATTTCTGTGATATT
AGAACCAGAATATAAAGACAAATTAGTGACTCCTCTTATTATTGTAGAAGGTGAAGGAA
AAATATACCATAATAAGAATGATAGTTTTAATCGTGAAGAACCGTATTTTCTAAAAATA
CGACCTACGTTAATGAATCCTATATTATATCAGATTATGGAATGCATTTATAGAGATCT
CAATTATTTGGATCCCAGAGAATACGATGGATGAAAAACATTTAAAGATTGTCATCTGT
ATATTAACGGAAATAGGATTATGTCCGCCGACGTAAAATATTTGAAGAATGGTAAACCT
GTAGGAGAAAAATTATCCGTATCCAAGGAAATAGATAAACTGGTTAAAAAAGATCCACA

SEQUENCE LISTING

<110> Bavarian Nordic A/S

<120> Vaccinia virus host range genes to increase the titer of avipoxviruses

<130> BN48PCT

<150> DK PA 2002 01189

<151> 2002-09-08

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 615

<212> DNA

<213> MVA

<220>

<221> estimated promoter sequence for C7L in MVA

<222> (1)..(162)

<223>

<220>

<221> CDS

<222> (163)..(615)

<223>

<400> 1
attaataaac tttaagacat gtgtgttata ctaagatggt tggcttattc catagtagct 60
tgtggaattt ataaacttat gatagtaaaa ctagtaccca atatgtaaag atgaaaaagt 120
aaattactat taacgccgctc ggtattcggt catccattca gt atg ggt ata cag 174
Met Gly Ile Gln
1

cac gaa ttc gac atc att att aat gga gat atc gcg ttg aga aat tta 222
 His Glu Phe Asp Ile Ile Ile Asn Gly Asp Ile Ala Leu Arg Asn Leu
 5 10 15 20
 cag tta cat aaa ggg gat aac tac gga tgc aaa cta aaa att att tcg 270
 Gln Leu His Lys Gly Asp Asn Tyr Gly Cys Lys Leu Lys Ile Ile Ser
 25 30 35
 aat gat tac aag aaa tta aag ttt aga ttc att ata cgc cca gat tgg 318
 Asn Asp Tyr Lys Lys Leu Lys Phe Arg Phe Ile Ile Arg Pro Asp Trp
 40 45 50
 tcg gaa atc gac gag gtc aaa gga tta acc gta ttt gca aac aac tat 366
 Ser Glu Ile Asp Glu Val Lys Gly Leu Thr Val Phe Ala Asn Asn Tyr
 55 60 65
 gcg gtg aaa gtt aat aag gta gat gac acg ttc tat tac gta ata tat 414
 Ala Val Lys Val Asn Lys Val Asp Asp Thr Phe Tyr Tyr Val Ile Tyr
 70 75 80
 gag gct gta ata cat ctg tat aac aaa aaa aca gag ata ttg att tat 462
 Glu Ala Val Ile His Leu Tyr Asn Lys Lys Thr Glu Ile Leu Ile Tyr
 85 90 95 100
 tct gat gat gag aac gaa ctc ttt aaa cac tat tac cca tac atc agt 510
 Ser Asp Asp Glu Asn Glu Leu Phe Lys His Tyr Tyr Pro Tyr Ile Ser
 105 110 115
 cta aat atg att agt aaa aag tat aaa gtt aaa gaa gaa aac tac tca 558
 Leu Asn Met Ile Ser Lys Lys Tyr Lys Val Lys Glu Glu Asn Tyr Ser
 120 125 130
 tcc ccg tat ata gaa cat ccg tta atc ccg tat aga gat tat gag tcc 606
 Ser Pro Tyr Ile Glu His Pro Leu Ile Pro Tyr Arg Asp Tyr Glu Ser
 135 140 145
 atg gat taa 615
 Met Asp
 150

<210> 2

<211> 150

<212> PRT

<213> MVA

<400> 2

Met Gly Ile Gln His Glu Phe Asp Ile Ile Ile Asn Gly Asp Ile Ala
 1 5 10 15
 Leu Arg Asn Leu Gln Leu His Lys Gly Asp Asn Tyr Gly Cys Lys Leu
 20 25 30
 Lys Ile Ile Ser Asn Asp Tyr Lys Lys Leu Lys Phe Arg Phe Ile Ile
 35 40 45
 Arg Pro Asp Trp Ser Glu Ile Asp Glu Val Lys Gly Leu Thr Val Phe
 50 55 60

Ala Asn Asn Tyr Ala Val Lys Val Asn Lys Val Asp Asp Thr Phe Tyr
65 70 75 80

Tyr Val Ile Tyr Glu Ala Val Ile His Leu Tyr Asn Lys Lys Thr Glu
85 90 95

Ile Leu Ile Tyr Ser Asp Asp Glu Asn Glu Leu Phe Lys His Tyr Tyr
100 105 110

Pro Tyr Ile Ser Leu Asn Met Ile Ser Lys Lys Tyr Lys Val Lys Glu
115 120 125

Glu Asn Tyr Ser Ser Pro Tyr Ile Glu His Pro Leu Ile Pro Tyr Arg
130 135 140

Asp Tyr Glu Ser Met Asp
145 150

<210> 3

<211> 1001

<212> DNA

<213> Canarypoxvirus

<400> 3

atactattct tcacggtaca tttaaaaaaa ggaatatagt cagaaacagg aaatatactt	60
tcactataac atggtctaata ttcgaatgtc cgacgtagg agacgtagg tcttcttcac	120
ctaataacctg taatagagta gtttagacg gtagtagata cgttacaaa acctttaatg	180
atacaatata aatggaacta actagagaaa cgctgatatt ttaggcatt actgtactag	240
tagtagtaat gatcatatct gggttctcac taatattgag attgatacct ggtgtatatt	300
catcagttat tagatcgtag ttcgtaggag ggaaaatatt aagatttatg gaggtattct	360
ctactgttat gtttatacca tcattagtaa tactttatac agcatatata aggaaatcta	420
aagtgaaaaa taactaaata ttatagtatt tgtaataaat ggctactgga gagattcgtc	480
ttattatagg gcctatgttt tcaggtaaaa caacagaatt agttagatta ataagaagat	540
ttatgatatc gggacgtaaa tgtataataa taaaacattg tagtgattcc cgttataccg	600
aaggagattt agaagctata tatactcatg ataaaatttc gatggaagca ctatcgtaga	660
gcaaattatt acctttaata cctaaaattg ataactttga agtaataggt atagacgaag	720
gacagttttt tgaagatata gtagaattta gtgagattat ggctaataag ggtaaaactg	780
taatcatagc ggctttaaat ggagatttca aacgacaatt atttggaac atatttaaac	840
tattatcttt atcagaatca gttactagtt taactgctat ttgtgcagtt tgtaaaaacg	900
aagcatcttt ttctaagcgc atgactgatg ataaagatgt aaaagttata ggaggtaaag	960

aaatgtatac tgctgtttgt agaaaatgct ttttatgagt c

1001

<210> 4

<211> 1003

<212> DNA

<213> Canarypoxvirus

<400> 4
taatatacgt actaaatact tgtacgtaca actatgttag aataatttgc ttagtatagt 60
atataaacia gtatgtaaaa aataaaattg atataaaagt agtcttctat tccgaacaat 120
aactatacaa aatggattta gatattaaat cttgcagaag tatttacaaa atatgggata 180
aatatcattt tatgacaggg tataaatata aaaatgataa acagagattt aaaattacaa 240
tttactgtaa atgtgattgt tctatcaaag aatatcctta tagatttggt actgagaaac 300
tgcttttaat gtatattatt aataagttta gaggaagta tctaataaaa attaggatag 360
aaccatagtg taaaaattaa atcatatatc aatacatgtc agttttttat cgaaaaatgg 420
atttataaat aaaatgaaaa ataacttgaa tgaaggaaaa aataaccatg agtaaaaaac 480
cagtaaagac ggtccagcgt agacgtggaa acgatgagga taataagttt acttgatcc 540
aagcgctaga acatgcaaaa agcttatgta ctaaaaataa taaaatagtt aaatctgtta 600
aactatcaca atctctcttt aagtcattta acaatatttc tgtgatatta gaaccagaat 660
ataaagacaa attagtact cctcttatta ttgtagaagg tgaaggaaaa atataccata 720
ataagaatga tagttttaat cgtgaagaac cgtattttct aaaaatacga cctacgttaa 780
tgaatcctat attatatcag attatggaat gcatttatag agatctcaat tatttgatc 840
ccgagaatac gatggatgaa aaaacattta aagattgtca tctgtatatt aacggaaata 900
ggattatgtc cgccgacgta aaatatttga agaatggtaa acctgtagga gaaaaattat 960
ccgtatccaa ggaaatagat aaactgggta aaaaagatcc aca 1003

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/86 C07K14/07 A61K39/275 A61K35/76 C12N5/10
C12N15/69

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, CHEM ABS Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FANG ZHI-YU ET AL: "Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells" VIROLOGY, vol. 291, no. 2, 20 December 2001 (2001-12-20), pages 272-284, XP002263751 ISSN: 0042-6822	18-26
Y	the whole document	1-28
X	WO 98 40501 A (VIROGENETICS CORP) 17 September 1998 (1998-09-17)	18-26
Y	the whole document	1-28
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

3 December 2003

Date of mailing of the international search report

22/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Valcarcel, R

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SOMOGYI P ET AL: "FOWLPOX VIRUS HOST RANGE RESTRICTION: GENE EXPRESSION, DNA REPLICATION, AND MORPHOGENESIS IN NONPERMISSIVE MAMMALIAN CELLS" VIROLOGY, ACADEMIC PRESS, ORLANDO, US, vol. 197, no. 1, November 1993 (1993-11), pages 439-444, XP001083667 ISSN: 0042-6822 the whole document	1-28
Y	PERKUS M E ET AL: "VACCINIA VIRUS HOST RANGE GENES" VIROLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 179, 1990, pages 276-286, XP000255782 ISSN: 0042-6822 the whole document	1-28
Y	WYATT L S ET AL: "Marker Rescue of the Host Range Restriction Defects of Modified Vaccinia Virus Ankara" VIROLOGY, ACADEMIC PRESS, ORLANDO, US, vol. 251, no. 2, 25 November 1998 (1998-11-25), pages 334-342, XP004445563 ISSN: 0042-6822 cited in the application the whole document	1-28
Y	BEATTIE E ET AL: "HOST-RANGE RESTRICTION OF VACCINIA VIRUS E3L-SPECIFIC DELETION MUTANTS" VIRUS GENES, KLUWER ACADEMIC PUBLISHERS, BOSTON, US, vol. 12, no. 1, 1996, pages 89-94, XP000990662 ISSN: 0920-8569 the whole document	1-28
A	US 5 833 975 A (COX WILLIAM I ET AL) 10 November 1998 (1998-11-10) the whole document	1-28
A	WO 02 056668 A (US GOVERNMENT ; FERRIS ANDREA L (US); HUGHES STEPHEN H (US)) 25 July 2002 (2002-07-25) the whole document	1-28

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/08359

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 13 and 14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 03/08359

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9840501	A	17-09-1998	US 5990091 A	23-11-1999
			AU 746402 B2	02-05-2002
			AU 6158498 A	29-09-1998
			EP 0970226 A1	12-01-2000
			JP 2001514518 T	11-09-2001
			US 6130066 A	10-10-2000
			WO 9840501 A1	17-09-1998
<hr/>				
US 5833975	A	10-11-1998	US 5378457 A	03-01-1995
			US 5155020 A	13-10-1992
			AU 719456 B2	11-05-2000
			AU 5645798 A	04-06-1998
			AU 684070 B2	04-12-1997
			AU 6165294 A	15-08-1994
			CA 2153336 A1	04-08-1994
			EP 0680331 A1	08-11-1995
			JP 9503902 T	22-04-1997
			WO 9416716 A1	04-08-1994
			US 2003198623 A1	23-10-2003
			US 5942235 A	24-08-1999
			US 6265189 B1	24-07-2001
			US 6537594 B1	25-03-2003
			AT 247163 T	15-08-2003
			AU 701599 B2	04-02-1999
			AU 1001197 A	15-05-1997
			AU 701781 B2	04-02-1999
			AU 1001297 A	15-05-1997
			AU 672359 B2	03-10-1996
			AU 1587192 A	06-10-1992
			AU 699903 B2	17-12-1998
			AU 6051396 A	24-10-1996
			CA 2105277 A1	08-09-1992
			DE 69233158 D1	18-09-2003
			EP 1367128 A1	03-12-2003
			EP 0575491 A1	29-12-1993
			JP 6505874 T	07-07-1994
			KR 242671 B1	02-03-2000
			KR 263278 B1	15-07-2000
			KR 263279 B1	15-07-2000
			US 5503834 A	02-04-1996
			US 6267965 B1	31-07-2001
			WO 9215672 A1	17-09-1992
			US 5494807 A	27-02-1996
			US 6596279 B1	22-07-2003
			US 5759552 A	02-06-1998
			US 5756102 A	26-05-1998
			US 5766597 A	16-06-1998
			US 5641490 A	24-06-1997
			US 5766598 A	16-06-1998
			US 5863542 A	26-01-1999
			US 5756103 A	26-05-1998
			US 5766599 A	16-06-1998
			US 5989561 A	23-11-1999
			US 5759553 A	02-06-1998
			US 5744141 A	28-04-1998
			US 5843456 A	01-12-1998
			US 5759841 A	02-06-1998
			US 5997878 A	07-12-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 03/08359

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 02056668 A	25-07-2002	WO 02056668 A2	25-07-2002